Skip to main content
. 2024 Jan 2;15:89. doi: 10.1038/s41467-023-44310-y

Fig. 6. Transgenic IL-12 promotes antitumor activity and persistence of GD2.CAR(I)IL12 NKTs in a re-challenge neuroblastoma tumor model.

Fig. 6

a Schematic representation of tumor re-challenge in the metastatic xenograft neuroblastoma model. Mice were engrafted i.v. with 1 × 106 CHLA-255 Firefly-luciferase labeled neuroblastoma tumor cells. Seven days later mice received i.v. 1 × 107 CAR-NKTs. Mice that were tumor free at day 64, received a second i.v injection of 1 × 106 CHLA-255 cells. A group of mice infused with CHLA-255 cells only was used as a second control for this model. b, c Representative tumor BLI (b) and BLI tumor kinetics (c). Thin lines represent individual mice, and bold lines represent the mean for the group; n = 9 mice for CD19.CAR(I)IL12 and n = 10 mice for GD2.CAR or GD2.CAR(I)IL12. Source data are provided as a Source Data file. d Kaplan–Meier survival curve showing tumor-free survival; n = 9 mice for CD19.CAR(I)IL12 and n = 10 mice for GD2.CAR or GD2.CAR(I)IL12, ***p = 0.0004; log-rank Mantel-Cox test. Source data are provided as a Source Data file. e Quantification of human NKTs (iNKT+CD45+) in peripheral blood samples collected 4 weeks after NKT infusion. Mean is shown; n = 9 mice for CD19.CAR(I)IL12 and n = 10 mice for GD2.CAR or GD2.CAR(I)IL12; **p = 0.0038, ***p = 0.0005, two-tailed unpaired t test. Source data are provided as a Source Data file. f Quantification of human IL-12, IFN-γ, GM-CSF and IL-2 in the serum of mice 4 weeks after the injection of CD19.CAR(I)IL12, GD2.CAR or GD2.CAR(I)IL12 NKTs. Mean is shown; n = 10 mice; IL-12 ***p = 0.0001, *p = 0.0250; IFN-γ *p = 0.0453; GM-CSF **p = 0.0054; IL-2 ****p < 0.0001; two-tailed paired t test. Source data are provided as a Source Data file. G. Genes differentially expressed in CAR.GD2(I)IL12 NKTs collected at the time of euthanasia versus IL12(I)GFP NKTs collected in vivo at day 30.